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Objective: In a preliminary study, we found that recently identiﬁed catabolic regulators of osteoarthritis
(OA), including hypoxia-inducible factor (HIF)-2a and members of the zinc-ZIP8-MTF1 axis, upregulate
the E3 ubiquitin ligase, Atrogin-1 (encoded by Fbxo32), in chondrocytes. As the ubiquitination/protea-
somal degradation pathways are tightly regulated to modulate the expression of catabolic factors in
chondrocytes, we examined the in vivo functions of Atrogin-1 in mouse models of OA.
Methods: The mRNA and protein levels of Atrogin-1 and other regulators of OA were determined in
primary cultured mouse chondrocytes, OA human cartilage, and OA cartilage from wild-type (WT) and
Fbxo32-knockout (KO) mice subjected to destabilization of the medial meniscus or intra-articular (IA)
injection of adenoviruses expressing HIF-2a (Ad-Epas1), ZIP8 (Ad-Zip8), or Atrogin-1 (Ad-Fbxo32). The
effect of Atrogin-1 overexpression on the cartilage of WT mice was examined by IA injection of Ad-
Fbxo32.
Results: Atrogin-1 mRNA levels in chondrocytes were markedly increased by treatment with interleukin-
1b, HIF-2a, and members of the zinc-ZIP8-MTF1 axis. Atrogin-1 protein levels were also increased in OA
cartilage from humans and various mouse OA models. However, the forced overexpression of Atrogin-1
in chondrocytes did not modulate the expression of cartilage matrix molecules or matrix-degrading
enzymes. Moreover, overexpression of Atrogin-1 in the mouse joint tissues failed to cause OA patho-
genesis, and Fbxo32 knockout failed to affect post-traumatic OA cartilage destruction in mice.
Conclusions: Although Atrogin-1 is upregulated in OA cartilage, overexpression of Atrogin-1 in the joint
tissues or knockout of Fbxo32 does not affect OA cartilage destruction in mice.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Mechanical stress and inﬂammatory responses in joint tissues
promote osteoarthritic (OA) cartilage destruction by inducing
extracellular matrix (ECM) breakdown and synovial inﬂamma-
tion1. Several transcription factors have been shown to upregulate
the expressions of the matrix metalloproteases (MMPs) and
aggrecanases that are involved in degrading the cartilage ECM2.
Our group recently identiﬁed the transcription factors, hypoxia-
inducible factor (HIF)-2a and metal-regulatory transcription fac-
tor 1 (MTF1), as being relevant to the pathogenic changes seen inJ.-S. Chun, School of Life Sci-
Buk-Gu, Gwangju 61005, Re-
er Ltd on behalf of Osteoarthritis R
d/4.0/).
t al., Upregulation of Atrogin-
e (2016), http://dx.doi.org/10OA chondrocytes3,4. We demonstrated that activation of the zinc-
ZIP8-MTF1 axis (i.e., upregulation of the zinc importer ZIP8, an
increase in the ZIP8-mediated zinc inﬂux, and activation of the
zinc-dependent transcription factor, MTF1) in response to me-
chanical stress and pro-inﬂammatory cytokines can upregulate
matrix-degrading enzymes in chondrocytes, leading to cartilage
destruction4. Similarly, we showed that HIF-2a, which is tran-
scriptionally upregulated in chondrocytes by mechanical stress
and pro-inﬂammatory cytokines, increases the expression of
matrix-degrading enzymes in chondrocytes3.
In a preliminary study, we used microarray analysis to identify
target genes of HIF-2a, ZIP8, and MTF1 in chondrocytes. We found
that Atrogin-1 is upregulated as a common target of these catabolic
regulators of OA in primary cultured mouse articular chondrocytes.
Atrogin-1, also known as F-Box protein 32 (FBXO32, encoded by
Fbxo32), was initially identiﬁed as a muscle-speciﬁc E3 ubiquitin
ligase required for skeletal muscle atrophy5. This is particularlyesearch Society International. This is an open access article under the CC BY-NC-ND
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pathway is tightly regulated to guide the expression of catabolic
factors in OA chondrocytes6. Indeed, blockade of this pathway was
shown to protect against OA cartilage destruction by inhibiting the
transcriptional activity of NF-kB, which regulates catabolic gene
expression during OA pathogenesis6. We also found that the
NAMPT protein is a target of HIF-2a, and their interaction stabilizes
HIF-2a protein stability by inhibiting the ubiquitin-mediated pro-
teasomal degradation pathway in chondrocytes, thereby increasing
the transcriptional activity of HIF-2a during OA pathogenesis7,8.
Because chondrocytic Atrogin-1 expression is increased by
catabolic regulators of OA pathogenesis, such as HIF-2a and MTF,
we herein examined the in vivo function of Atrogin-1 during OA
pathogenesis in mouse models. We report that although Atrogin-1
is upregulated in OA chondrocytes and cartilage, its upregulation is
neither sufﬁcient nor necessary for cartilage destruction in exper-
imental mouse models of OA.
Materials and methods
Human OA cartilage and experimental OA in mice
Human OA cartilage was sourced from individuals undergoing
arthroplasty3,4,7,8. Male mice (C57BL/6) were used for experi-
mental OA studies. All experiments were approved by the Gwangju
Institute of Science and Technology Animal Care and Use Com-
mittee. Fbxo32/ mice were generated using the CRISPR-Cas9
genome editing system (Macrogen, Inc., Seoul, Korea). All manip-
ulations were conducted with approval from the Macrogen Insti-
tutional Animal Care and Use Committee. Brieﬂy, four different
single-guide RNAs (sgRNAs) targeting the ﬁrst exon of Fbxo32
were generated by in vitro transcription. These sgRNAs and Cas9
recombinant proteins were co-injected into pronuclear-stage one-
cell mouse embryos, blastocysts derived from the injected em-
bryos were transplanted into foster mothers, and newborn pups
were obtained. DNA sequencing of multiple mouse lines was used
to examine deletions of the ﬁrst exon of Fbxo32. For experiments,
we selected a line harboring a 77-base pair deletion in the ﬁrst
exon that resulted in premature truncation of the Atrogin-1 pro-
tein (21 amino acids).
Experimental OA was induced by destabilization of the medial
meniscus (DMM) or intra-articular (IA) injection of adenoviruses
(once weekly for 3 weeks, 1  109 plaque forming units)
expressing HIF-2a (Ad-Epas1), ZIP8 (Ad-Zip8), or Atrogin-1 (Ad-
Fbxo32) (Vector Biolabs), as described previously3,4,7,8. At 8 weeks
after DMM surgery or 3 weeks after the ﬁrst IA injection, mice
were sacriﬁced, and histological and biochemical analyses were
performed. Cartilage destruction was examined by safranin-O
staining and scored using the Osteoarthritis Research Society
International (OARSI) grading system3,4,7,8. Cartilage sections
were immunostained for HIF-2a (ab8365; Abcam), ZIP8 (sc-
133415; Santa Cruz Biotechnology), and Atrogin-1 (ab198958;
Abcam).
Chondrocytes, adenoviral infection, and biochemical analysis
Chondrocytes were isolated from the femoral condyles and
tibial plateaus of mice3,4,7,8. On day 2 of culture, the chondrocytes
were treated as indicated in each experiment or infected with
adenoviruses at the indicated multiplicity of infection (MOI). The
mRNA levels of mouse Atrogin-1 were detected by reverse
transcription-polymerase chain reaction (RT-PCR) and measured
by quantitative RT-PCR (qRT-PCR) using speciﬁc primers (sense,
50-TCAAAGGCCTCACGATCACC-30; antisense, 50-CCTCAATGACG-
TATCCCCCG-30). The primer sequences for the additionalPlease cite this article in press as: Kim H-E, et al., Upregulation of Atrogin-
of osteoarthritis, Osteoarthritis and Cartilage (2016), http://dx.doi.org/10indicated molecules were as described previously3,4,7,8. Atrogin-1
protein levels were detected by Western blotting (sc-166806;
Santa Cruz Biotechnology).
Statistical analysis
The n number indicated in each ﬁgure corresponds to the
number of statistically independent observations or the number of
mice used. Data quantiﬁed on an ordinal grading system, such as
the OARSI grade, were analyzed using non-parametric statistical
methods. For qRT-PCR data, the Student's t-test and analysis of
variance (ANOVA) with post-hoc tests were used for pair-wise
comparisons and multi-comparisons, respectively, after we ﬁrst
conﬁrmed a normal distribution using the ShapiroeWilk test. All
data are presented as the mean and the 95% conﬁdence intervals
(CIs).
Results
Atrogin-1 is upregulated in OA chondrocytes and cartilage
To begin examining whether Atrogin-1 plays a role in OA
pathogenesis, we ﬁrst determined the expression of Atrogin-1 in
primary cultured mouse articular chondrocytes. qRT-PCR analyses
revealed that the mRNA levels of Atrogin-1 were markedly
increased in chondrocytes treated with IL-1b or expressing HIF-2a
(encoded by Epas1)3, ZIP84, or MTF14 [Fig.1(A)]. At the protein level,
we found that Atrogin-1 was markedly elevated in OA-affected
regions of human cartilage, compared with undamaged areas of
the same sample [Fig. 1(B)], and in OA cartilage of mice subjected to
DMM surgery or IA injection of Ad-Epas1 or Ad-Zip8 [Fig. 1(C)].
These results suggest that Atrogin-1may be functionally relevant in
chondrocytes during OA pathogenesis.
Atrogin-1 is not sufﬁcient or necessary for OA cartilage destruction
in mice
Based on the above ﬁndings, we assessed whether Atrogin-1
might regulate cartilage destruction in OA. We ﬁrst examined the
capacity of Atrogin-1 to regulate the expression levels of matrix-
degrading enzymes and cartilage matrix molecules in primary
cultured mouse articular chondrocytes. However, the Ad-Fbxo32
infection-mediated overexpression of Atrogin-1 in chondrocytes
did not alter the expression levels of catabolic matrix-degrading
enzymes (e.g., MMP3, MMP13, and ADAMTS5) or anabolic carti-
lage matrix molecules (e.g., type II collagen and aggrecan)
[Fig. 2(A)].
To examine the potential in vivo function of Atrogin-1 in OA
pathogenesis, we performed IA injection of Ad-Fbxo32 into mouse
knee joints. We previously demonstrated that effective gene de-
livery could be achieved using this method3,4,7,8. Indeed, we
conﬁrmed that Ad-Fbxo32 injection led to the overexpression of
Atrogin-1 in cartilage [Fig. 2(B)] and other joint tissues, including
the meniscus and synovium (data not shown). However, further
assessments revealed that this overexpression did not cause carti-
lage destruction [Fig. 2(B)] or synovial inﬂammation [Fig. 2(C)].
Thus, Atrogin-1 overexpression is not sufﬁcient to trigger OA
pathogenesis in this model.
Finally, to examine whether Atrogin-1 upregulation is neces-
sary for OA pathogenesis, we generated whole-body Fbxo32-
knockout (KO) mice using the RNA-guided CRISPR-Cas9 system9.
We conﬁrmed that Atrogin-1 was not detected in chondrocytes
of the cartilage of Fbxo32/ mice [Fig. 2(D) and (E)], and found
that these mice exhibited normal limb, cartilage, and bone
development (data not shown). Our further experiments1/FBXO32 is not necessary for cartilage destruction in mouse models
.1016/j.joca.2016.07.008
Fig. 1. Atrogin-1 is upregulated in OA chondrocytes and cartilage. (A) Atrogin-1 mRNA levels were quantiﬁed by qRT-PCR in chondrocytes stimulated with IL-1b (n ¼ 8) or infected
with control adenovirus (Ad-C; MOI, 800) or the indicated MOI of Ad-Epas1 (n ¼ 8), Ad-Zip8 (n ¼ 8), and Ad-Mtf1 (n ¼ 8). (B and C) Representative images of Alcian blue and
immunohistochemical staining for Atrogin-1 in human OA cartilage (B; n ¼ 5) and safranin-O staining and immunostaining for Atrogin-1 in cartilage sections frommice subjected to
DMM surgery or IA injection of Ad-C (n ¼ 5), Ad-Epas1 (n ¼ 5), or Ad-Zip8 (C) (n ¼ 5). Values are the means ±95% CI. Scale bar: 50 mm.
Fig. 2. Upregulation of Atrogin-1 is not sufﬁcient or necessary for OA cartilage destruction in mice. (A) The mRNA and protein levels of the indicated molecules were detected in
chondrocytes infected with the indicated MOI of Ad-Fbxo32. (B) Representative images of Atrogin-1 immunostaining (left) and safranin-O staining (right) in cartilage sections from
mice subjected to IA injection with Ad-C (n ¼ 8) or Ad-Fbxo32 (n ¼ 8). (C) Representative images of H&E staining in knee joint sections frommice subjected to IA injection with Ad-C
(n ¼ 8) or Ad-Fbxo32 (n ¼ 8). (D) Representative images of Atrogin-1 immunostaining in cartilage sections of wild-type (WT; n ¼ 5) and Fbxo32-knockout (KO) mice (n ¼ 5). (E)
Genotype and mRNA levels of Atrogin-1 in chondrocytes of WT and Fbxo32 KO mice. (F) Representative images of safranin-O staining, OARSI grade, and osteophyte maturity in
sham- and DMM-operated wild-type (WT; n ¼ 8) and Fbxo32/ (n ¼ 8). Values are the means ±95% CI. Scale bar: 50 mm.
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similar degrees of cartilage destruction and osteophyte formation
following DMM surgery [Fig. 2(F)], indicating that genetic abla-
tion of Fbxo32 does not affect DMM-induced OA pathogenesis.Please cite this article in press as: Kim H-E, et al., Upregulation of Atrogin-
of osteoarthritis, Osteoarthritis and Cartilage (2016), http://dx.doi.org/10Collectively, our gain-of-function (IA injection of Ad-Fbxo32) and
loss-of-function (in Fbxo32/ mice) studies demonstrate that
Atrogin-1 is neither sufﬁcient nor necessary for experimental OA
in mice.1/FBXO32 is not necessary for cartilage destruction in mouse models
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The ubiquitin-activating (E1), ubiquitin-conjugating (E2), and
ubiquitin ligase (E3) enzymes catalyze the formation of an iso-
peptide bond between ubiquitin and a substrate lysine, resulting
in either monoubiquitination or polyubiquitination. The ubiq-
uitination of target proteins regulates various cellular processes,
including the degradation of target proteins via the 26S protea-
some, the intracellular localization of proteins, and protein in-
teractions10. It has been reported that the E3 ubiquitin ligase,
Smurf2, is upregulated in OA cartilage, and that overexpression of
Smurf2 in chondrocytes results in cartilage destruction11. Atrogin-
1 was initially identiﬁed as a muscle-speciﬁc E3 ubiquitin ligase
that is required for skeletal muscle atrophy5. Subsequent studies
showed that IL-1b stimulates Atrogin-1 expression in differenti-
ated myotubes and stimulates myotube catabolism12. IL-1b is a
major pro-inﬂammatory cytokine associated with cartilage
destruction and the upregulation of matrix-degrading enzymes in
chondrocytes13. We therefore hypothesized that Atrogin-1 may
catabolically regulate OA pathogenesis by modulating catabolic
gene expression in chondrocytes.
Here, we report that Atrogin-1 is upregulated in chondrocytes
treated with all examined catabolic regulators of OA pathogen-
esis (IL-1b, HIF-2a, ZIP8, and MTF1), in human OA cartilage, and
also in the OA cartilage of various mouse models. However, the
overexpression of Atrogin-1 in chondrocytes did not alter the
expression levels of catabolic or anabolic genes. Moreover,
ectopic expression of Atrogin-1 in joint tissues or genetic abla-
tion of its encoding gene, Fbxo32, failed to affect the pathogenesis
of experimental OA induced in mice. Although our results sug-
gest that the upregulation of Atrogin-1 in OA cartilage is neither
sufﬁcient nor necessary for the pathogenesis of OA, its speciﬁc
upregulation by catabolic regulators of OA in chondrocytes and
its increased expression in human and mouse OA cartilage sug-
gest that this protein could be a useful biomarker for OA
progression.
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